Corpus Intelligence IC Memo — WHS - GREENE 2026-04-26 15:54 UTC
IC Memo — WHS - GREENE
Investment Committee Memorandum | PA | 18 beds | Grade D | EBITDA uplift $1.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WHS - GREENE

CCN 390150 | GREENE, PA | 18 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

WHS - GREENE is a 18-bed under-performing / distressed in GREENE, PA with $16.3M in net patient revenue and a -26.4% operating margin. The hospital serves a payer mix of 3.7% Medicare, 1.7% Medicaid, and 94.5% commercial.

Thesis: Turnaround. Our ML models identify $1.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -26.4% to -19.0% (+736bps).

Net Revenue HCRIS$16.3M
Current EBITDA COMPUTED$-4.3M
Operating Margin COMPUTED-26.4%
Occupancy HCRIS22.8%
Revenue / Bed COMPUTED$905K
Net-to-Gross HCRIS35.4%
Distress Probability ML53.6%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
40
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -26.4% places it below the state median. Among 40 size-comparable peers (9-36 beds), the median margin is 0.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (9-36), prioritizing same-state peers. 40 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WHS - GREENE (Target)PA18$16.3M-26.4%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%
WELLSPAN SURGERY AND REHAB HOSPA25$120.2M2.8%
UPMC LITITZPA36$114.5M14.2%
LVH-COORDINATED ALLENTOWNPA20$89.6M2.3%
CHARLES COLE MEMORIAL HOSPITALPA25$88.1M-9.0%
WELLSBOROPA25$85.6M2.3%
FRICK HOSPITALPA33$67.4M9.3%
PENN HIGHLANDS ELKPA25$67.4M-0.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$342K+210bp18mo
Cost to Collect4.5%2.5%$326K+200bp12mo
Denial Rate Reduction12.0%6.5%$323K+198bp12mo
A/R Days Reduction5200.0%3800.0%$198K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$342K
Cost to Collect
$326K
Denial Rate Reduction
$323K
A/R Days Reduction
$198K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.2M
Current EBITDA$-4.3M
+ RCM Uplift+$1.2M
Pro Forma EBITDA$-3.1M
Current Margin-26.4%
Pro Forma Margin-19.0%
WC Released (1x)$625K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-6.6M$-16.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-6.6M$-20.1M0.00x-100.0%
Bull Case9.0x11.0x$-5.9M$-18.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-5.9M$-21.7M0.00x-100.0%
Bear Case11.0x10.0x$-7.3M$-20.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-7.3M$-24.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 22.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 40 hospitals with 9-36 beds
  • Same-state prioritization (n=41)
  • Comp margins: P25=-14.3% / P50=0.0% / P75=8.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.